Cantor Fitzgerald Downgrades Sarepta Therapeutics to Neutral, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has downgraded Sarepta Therapeutics (NASDAQ:SRPT) from Overweight to Neutral and lowered the price target from $166 to $40.
October 31, 2023 | 1:51 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sarepta Therapeutics has been downgraded from Overweight to Neutral by Cantor Fitzgerald, with a significant reduction in price target from $166 to $40.
The downgrade from Overweight to Neutral indicates a less optimistic outlook for the company's stock. The significant reduction in price target from $166 to $40 suggests that the analyst believes the stock is overvalued at its current price, which could lead to a decrease in the stock's price in the short term.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100